- Home
- MPTI vs AGEN Comparison
MPTI vs AGEN Comparison
Compare MPTI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPTI
- AGEN
- Stock Information
- Founded
- MPTI 1965
- AGEN 1994
- Country
- MPTI United States
- AGEN United States
- Employees
- MPTI N/A
- AGEN N/A
- Industry
- MPTI
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MPTI
- AGEN Health Care
- Exchange
- MPTI Nasdaq
- AGEN Nasdaq
- Market Cap
- MPTI 127.2M
- AGEN 142.8M
- IPO Year
- MPTI N/A
- AGEN 2000
- Fundamental
- Price
- MPTI $48.59
- AGEN $4.55
- Analyst Decision
- MPTI
- AGEN Buy
- Analyst Count
- MPTI 0
- AGEN 2
- Target Price
- MPTI N/A
- AGEN $14.50
- AVG Volume (30 Days)
- MPTI 27.1K
- AGEN 387.3K
- Earning Date
- MPTI 11-12-2025
- AGEN 11-11-2025
- Dividend Yield
- MPTI N/A
- AGEN N/A
- EPS Growth
- MPTI 45.88
- AGEN N/A
- EPS
- MPTI 2.57
- AGEN N/A
- Revenue
- MPTI $52,033,000.00
- AGEN $101,706,000.00
- Revenue This Year
- MPTI $12.06
- AGEN $60.49
- Revenue Next Year
- MPTI $7.34
- AGEN N/A
- P/E Ratio
- MPTI $18.93
- AGEN N/A
- Revenue Growth
- MPTI 16.52
- AGEN N/A
- 52 Week Low
- MPTI $28.62
- AGEN $1.38
- 52 Week High
- MPTI $60.00
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- MPTI 63.17
- AGEN 48.05
- Support Level
- MPTI $46.16
- AGEN $4.36
- Resistance Level
- MPTI $48.74
- AGEN $5.20
- Average True Range (ATR)
- MPTI 1.51
- AGEN 0.28
- MACD
- MPTI 0.32
- AGEN 0.05
- Stochastic Oscillator
- MPTI 94.13
- AGEN 40.91
About MPTI M-tron Industries Inc.
M-Tron Industries Inc is a diversified holding company with subsidiaries engaged in designing, manufacturing, and marketing high-engineered, high-reliability frequency and spectrum control products used to control the frequency or timing of signals in electronic circuits in various applications. The company's serving markets are aerospace and defense, space, and avionics. The company offers products such as microwave and millimeter wave filters; cavity, crystal, ceramic, lumped element, and switched filters; crystal resonators, integrated microwave assemblies, and solid-state power amplifier products.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).